低氧暴露对运动性贫血大鼠抗氧化能力的影响

目的:观察低氧暴露对运动性贫血大鼠某些抗氧化酶的影响,探讨低氧条件下抗氧化系统的反应是否有利于改善运动性贫血。方法:实验于2005-07/09在广东省高等学校运动生物化学教学重点实验室完成。选择6周龄健康雄性SD大鼠40只,均为运动性贫血动物模型,大鼠适应环境1周后采用6周递增负荷跑台运动方式建立。按随机数字表法分为1h低氧暴露组、2h低氧暴露组和间歇性低氧暴露组、常氧恢复组,每组10只。采用人工常压低氧环境,低氧浓度控制在14.5%左右,按分组每天在常压低氧舱进行1,2h和间歇性低氧暴露(低氧暴露1h,中间间歇3h,再低氧暴露1h),其余时间在舱外常氧中自由活动,每周6d,持续3周。常氧恢复组大鼠在常氧中自由活动。3周后测试运动性贫血大鼠血清丙二醛含量、超氧化物歧化酶活性和血浆过氧化氢酶、谷胱甘肽过氧化酶活性。结果:纳入动物40只,均进入结果分析。①低氧暴露3周后1h低氧暴露组、2h低氧暴露组、间歇性低氧暴露组血清丙二醛含量均显著低于常氧恢复组[分别为(2.62±0.16),(2.60±0.22),(2.55±0.06),(3.36±0.34)μmol/L,P<0.05]。②低氧暴露3周后血清超氧化物歧化酶和血浆谷胱甘肽过氧化酶、过氧化氢酶活性均高于常氧恢复组,2h低氧暴露组与常氧恢复组比较差异有显著性意义[分别为(4239.68±169.53),(3190.30±339.40)μkat/L;(20622.46±2002.07),(15556.44±607.79)μkat/L;(50.01±6.67),(35.17±4.50)μkat/L,P<0.05]。③各低氧暴露组间除2h低氧暴露组血清超氧化物歧化酶活性显著高于1h低氧暴露组外[分别为(4239.68±169.53),(2126.41±161.20)μkat/L,P<0.05],其他指标组间差异无显著性意义(P>0.05)。结论:低氧暴露可提高运动性贫血大鼠机体的抗氧化能力,有利于促进运动性贫血的恢复。     

全层软骨缺损合并深部“微骨折”兔软骨修复情况

目的:观察在全层软骨缺损深部制造“微骨折”对兔软骨修复的影响。方法:实验于2003-04/10在同济医学院矫形外科实验室完成。实验用自制“微骨折”骨刀由管形不锈钢制作而成,分微骨刀内芯和外置套筒两部分。微骨刀近端配有可拆卸的螺帽,其远端为4枚锋利的钢钉,孔距为4mm,其连线呈正方形,孔隙深4mm,可深达松质骨内。取20只大白兔随机分2组,每组10只。用尖刀片在兔股骨内髁处切除6mm×6mm软骨组织造成全层关节软骨缺损,建立实验动物模型。实验组在缺损局部应用特制骨刀造成“微骨折”,对照组缺损局部不予特殊处理。分别在4周和8周每组各处死5只实验兔,作大体观察以及组织病理学检查。结果:①两组兔缺损修复处大体观察:在缺损处对照组只有肉芽组织和瘢痕组织生长,仅边缘有少量软骨组织生长,实验组在4周时大部分为软骨组织生长,而8周已全部被软骨组织修复。②组织病理学观察:实验组在4周时修复组织以纤维软骨为主,还有大量幼稚的透明软细胞,排列较紊乱,内混有一些纤维组织,与正常的关节软骨组织有一定的差异。而对照组修复组织均为红染的肉芽组织和纤维瘢痕组织,8周时,仅为瘢痕组织。③关节活动度的变化:术后各组动物关节活动度良好。结论:采用特制骨刀在全层软骨缺损的情况下合并“微骨折”,能使全层缺损的软骨组织得以修复。     

Anxiety and depression in children and adolescents with spinal cord injuries

Aim  To determine the levels of anxiety and depression in young people with spinal cord injuries (SCI) and their associated factors and outcomes.
Method  Children and adolescents aged 7 to 17 years at interview who had sustained SCI at least 1 year before the study were assessed using the Children's Depression Inventory, the Revised Children's Manifest Anxiety Scale, the Pediatric Quality of Life Inventory, the Children's Assessment of Participation and Enjoyment, and a demographic questionnaire designed for the study.
Results  The 118 participants (61 males, 57 females) had a mean age of 12 years 4 months, SD 3y 1mo, range 7-17y. Mean age at injury was 5 years 11 months, SD 4y 11m, range 0-16y; 89 participants (75%) had paraplegia and 29 (25%) had tetraplegia. Fifty-seven (52%) had complete injuries and 52 (48%) had incomplete injuries according to the American Spinal Injury Association impairment scale. Thirteen participants (13%) reported significant symptoms of anxiety, and seven (6%) reported significant levels of depression, which were comparable to the normative population. Age, race, and sex were not associated with anxiety or depression, but participants with shorter duration of injury were more likely to be anxious, and those with less functional independence were more likely to be depressed. Only one dimension of participation was associated with anxiety and depression, but all aspects of quality of life were decreased among those with anxiety or depression.
Interpretation  The levels of anxiety and depression in young people with SCI are comparable to the normative range. When anxiety and depression occur they are associated with reduced levels of quality of life.     

Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004–2008)

Background  Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD).
Aims  To evaluate the efficacy and safety of adalimumab on a nationwide clinical setting.
Methods  We used the Scottish Society of Gastroenterology network to identify and follow up the clinical outcomes of patients with CD treated with adalimumab over a 4-year period (2004–2008).
Results  A total of 98 patients received adalimumab - 100.5 patient follow-up years were recorded (64.3% females; median age at diagnosis of 20.7 years; 88.8% treated with 80/40 mg induction regimen. Eighty eight (89.8%) had previous infliximab with 29 (32.9%) primary nonresponders; 32 (32.6%) were corticosteroid-dependent; 47 (47.9%) were intolerant/resistant to most immunosuppressive therapies (two or more). In all, 60% of patients were in clinical remission at 1-year follow-up, with 30% and 55% requiring dose escalation to weekly therapy at 1-and 2-year follow-up respectively. Overall, 29 (29.6%) patients developed complications with eight nonfatal serious (8.2%) adverse events and 2 (2.0%) case fatalities (sepsis following perforation and disseminated colorectal cancer, respectively).
Conclusions  Adalimumab is efficacious in severe and refractory CD in the clinical setting, although there remain significant therapy- and disease-related risks of serious complications.     

Effects of ranitidine, given t.d.s., on intragastric and oesophageal pH in patients with gastrooesophageal reflux

The purpose of this study was to determine the effects of 150 mg ranitidine, 300 mg ranitidine or placebo, administered every 8 h, on gastro-oesophageal pH and heartburn parameters in reflux patients. Twelve symptomatic reflux patients received each of the three treatments in a randomized, double-blind, crossover fashion. Intragastric and oesophageal pH were monitored continuously for a 24 h period. Meals were standardized, consumed at set times and patients were allowed to recline and sleep from 23.00 hours until 06.00 hours only. The gastric record was analysed for the percentage of time that the pH was greater than or equal to 4. The oesophageal record was analysed for acid contact time (percentage time (%) pH less than or equal to 4.0) and reflux episode frequency. Finally, patients recorded each new episode of heartburn and graded daytime heartburn severity at the end of each hour. Ranitidine increased the median (%) time that the intragastric pH remained at or above 4, from 4.5 (placebo) to 33.9% (150 mg dose) and 33.3% (300 mg dose). Ranitidine dose-dependently reduced the median 24-hour oesophageal acid contact time from 13.3% (placebo) to 6.8% (150 mg dose) and 2.5% (300 mg dose). The 300 mg dose significantly reduced daytime heartburn episode frequency and severity while the 150 mg dose reduced heartburn severity only. We conclude that 150 and 300 mg doses of ranitidine administered every 8 h have major, sometimes dose-dependent effects on the objective parameters and symptoms of gastro-oesophageal reflux.     

The tobacco use research program at Oregon Research Institute

The research program at ORI deals with both adolescent and adult tobacco use and is guided by a behavioral framework which emphasizes the role of the social context in tobacco use onset, maintenance and cessation. Growing appreciation of the importance of social context variables, combined with an emerging recognition of the need for a public health rather than clinical perspective on tobacco use, have led to a focus on interventions in larger social systems such as schools, worksites, health care plans, and communities. This research requires attention to the science of behavior change at both the individual and organizational levels.     

Protection from gastrointestinal side-effects by azapropazone by its incorporation into a glucose—sodium acid citrate formulation

Addition of glucose and sodium citrate to azapropazone, in proportions of 1:1:1 by weight reduced gastric mucosal damage in rats and there was a trend towards reduction in radiolabelled faecal red cell loss in human volunteers compared with that with azapropazone alone. The glucose and citrate did not affect the pharmacokinetics of azapropazone, or its therapeutic efficacy. While no difference was observed in endoscopic injury and in symptomatic gastrointestinal complaints in a multicentre comparison in rheumatic patients, a striking reduction in symptoms was observed in those patients with a history of severe gastrointestinal intolerance to non-steroidal anti-inflammatory drugs.     

《中华男科学》杂志2000～2002年载文及引文分析

目的 :评价《中华男科学》杂志的地位和社会影响力。　方法 :用文献计量学方法对 2 0 0 0～ 2 0 0 2年《中华男科学》杂志载文及其引文情况进行统计分析。　结果 :除综述性文献和译文外 ,3年 16期共载文 34 3篇 ,其中333篇文献有引文 ,占载文总数的 97.0 8%;论著共计 183篇 ,占 5 3.35 %;基金项目论文 6 2篇 ,占总载文量的18.0 8%;载文量与基金项目论文篇数逐年增加 ;分布在全国 30个省及直辖市 ,作者中 43.37%为高级职称 ,拥有博士、硕士学位的占 40 .80 %;期刊与作者平均自引率为 6 .30 %、3.39%;文献发表 5年内被引用的频率最高 ,普赖斯指数为 5 6 .0 3%;引文语种以英文文献为主 ,期刊占引文总数的 83.0 2 %。　结论 :该刊拥有一批优秀的作者群体 ,具有很强的社会影响力以及广阔的发展前景 ,是一高质量的学术期刊。     

慢性骨盆疼痛综合征前列腺液16S rRNA基因检测及临床意义

目的 :通过前列腺液 16SrRNA基因的检测 ,探讨慢性骨盆疼痛综合征 (CPPS)的细菌感染性病因及其对抗生素疗效的预测价值。　方法 :用通用引物PCR法检测 5 9例CPPS病人前列腺液 (EPS)和初段尿 (VB1)细菌16SrRNA基因。若只在EPS检测到条带 ,或EPS信号比VB1强 10倍以上 ,则细菌信号判断为阳性。所有病人口服左氧氟沙星及阿奇霉素治疗 4周。与治疗前相比 ,治疗后症状严重性积分指数 (SSI)、症状频度问卷积分 (SFQ)、前列腺炎症状积分指数 (NIH CPSI)中疼痛问题的总积分 (quasi CPSI)减少 5 0 %以上 ,或病人主观总体评价改善5 0 %以上作为治疗有效的标准。　结果 :5 9例CPPS病人中细菌信号阳性 46例、阴性 13例。细菌信号阳性与阴性两组治疗有效率分别为 6 5 %～ 74%、0 ,疗效差异有极显著性 (P <0 .0 1)。　结论 :部分CPPS与细菌感染有关 ,前列腺 16SrRNA基因检测的结果对选择抗生素治疗有指导意义。